Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis

Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis

Abstract:: Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is α2-antiplasmin (α2AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be...

Full description

Bibliographic Details
Main Authors: Nikoletta Pechlivani, Basmah Alsayejh, Mansour Almutairi, Katie Simmons, Thembaninkosi Gaule, Fladia Phoenix, Noppadol Kietsiriroje, Sreenivasan Ponnambalam, Cédric Duval, Robert A.S. Ariëns, Christian Tiede, Darren C. Tomlinson, Ramzi A. Ajjan
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006414

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924006414

Similar Items